- Home
- CCOI vs DNLI Comparison
CCOI vs DNLI Comparison
Compare CCOI & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCOI
- DNLI
- Stock Information
- Founded
- CCOI 1999
- DNLI 2013
- Country
- CCOI United States
- DNLI United States
- Employees
- CCOI N/A
- DNLI N/A
- Industry
- CCOI Telecommunications Equipment
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CCOI Consumer Discretionary
- DNLI Health Care
- Exchange
- CCOI Nasdaq
- DNLI Nasdaq
- Market Cap
- CCOI 3.5B
- DNLI 3.1B
- IPO Year
- CCOI N/A
- DNLI 2017
- Fundamental
- Price
- CCOI $73.18
- DNLI $25.25
- Analyst Decision
- CCOI Buy
- DNLI Strong Buy
- Analyst Count
- CCOI 12
- DNLI 10
- Target Price
- CCOI $77.82
- DNLI $38.30
- AVG Volume (30 Days)
- CCOI 385.6K
- DNLI 794.6K
- Earning Date
- CCOI 08-08-2024
- DNLI 08-01-2024
- Dividend Yield
- CCOI 5.38%
- DNLI N/A
- EPS Growth
- CCOI N/A
- DNLI N/A
- EPS
- CCOI 0.95
- DNLI N/A
- Revenue
- CCOI $999,440,000.00
- DNLI $1,267,000.00
- Revenue This Year
- CCOI $19.79
- DNLI N/A
- Revenue Next Year
- CCOI $3.09
- DNLI $176.62
- P/E Ratio
- CCOI $76.78
- DNLI N/A
- Revenue Growth
- CCOI 48.73
- DNLI N/A
- 52 Week Low
- CCOI $50.80
- DNLI $14.56
- 52 Week High
- CCOI $86.00
- DNLI $25.90
- Technical
- Relative Strength Index (RSI)
- CCOI 59.85
- DNLI 59.58
- Support Level
- CCOI $68.75
- DNLI $24.12
- Resistance Level
- CCOI $74.12
- DNLI $25.69
- Average True Range (ATR)
- CCOI 2.02
- DNLI 1.07
- MACD
- CCOI -0.45
- DNLI 0.06
- Stochastic Oscillator
- CCOI 57.76
- DNLI 78.76
About CCOI Cogent Communications Holdings Inc.
Cogent carries over one fifth of the world's internet traffic over its network and is a broadband provider for businesses. Cogent's corporate customers are in high-rise office buildings; the firm provides them with two types of connections: dedicated internet access, which connects them to the internet, and virtual private networking, which offers an internal network for employees in different locations. Cogent's corporate customers are exclusively in North America and account for over half of the firm's revenue. Cogent's netcentric customers include internet service providers and content providers, to which Cogent provides internet transit. They hand traffic to Cogent in data centers and rely on Cogent to deliver it. About half of netcentric revenue is from outside the US.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.